Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients with desmoid tumors.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer ...

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve ...

The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...

Panelists discuss the emerging potential of KRAS inhibition in metastatic cancer treatment, exploring novel therapies and their promise for patients with KRAS-mutated tumors.

Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

Alfred L. Garfall, MD, emphasizes the critical importance of the National Institutes of Health funding for biomedical research.

The FDA has approved 2 biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and (Osenvelt), for all indications of their respective reference products (Prolia) and (Xgeva), Celtrion stated in a news release ...

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...